FibroGen, Inc.
FibroGen, Inc. (FGEN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FGEN · as of Sep 30, 2025
Ownership Breakdown
33
Institutional Holders
▲ 2 vs Q2
$13.87M
Total Inst. Value
▲ $8.25M vs Q2
4.05M
Shares Outstanding
freeFloat 88.58%
1.13M
13F Shares Held
▲ 72,210 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FGEN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 378.0K | 9.35% | 9.35% | $4.63B | Nov 17, 2025 | ▲ 42.0K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 235.3K | 5.82% | 5.82% | $2.88B | Nov 14, 2025 | ▼ 38.1K |
VANGUARD GROUP INC pharmaceutical preparations | 184.2K | 4.56% | 4.56% | $2.26B | Nov 7, 2025 | ▲ 6.2K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 110.3K | 2.73% | 2.73% | $1.35B | Nov 13, 2025 | ▼ 28.8K |
BLACKROCK, INC. pharmaceutical preparations | 84.8K | 2.10% | 2.10% | $1.04B | Nov 12, 2025 | — held |
MARSHALL WACE, LLP pharmaceutical preparations | 72.4K | 1.79% | 1.79% | $887.50M | Nov 13, 2025 | ▲ 149 |
PRIMECAP MANAGEMENT CO/CA/ pharmaceutical preparations | 58.9K | 1.46% | 1.46% | $721.27M | Nov 12, 2025 | ▼ 30.8K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 47.1K | 1.17% | 1.17% | $576.98M | Nov 14, 2025 | ▼ 8.4K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 43.7K | 1.08% | 1.08% | $535.23M | Nov 12, 2025 | ▼ 354 |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 40.2K | 99.50% | 99.50% | $492.67M | Nov 14, 2025 | ▲ 26.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
9
Increased
+100.3K shares4
New Positions
first time holders9
Decreased
−111.3K shares2
Sold Out
fully exitedNet shares change (top 50)
11.1K
+100.3K / −111.3K
Net new holders
+2
4 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FGEN insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
FibroGen, Inc. (FGEN) is primarily owned by institutional investors, who hold approximately 28.0% of total shares outstanding. Company insiders own approximately 11.42%, while retail and public investors account for the remaining 60.59%.
The largest institutional shareholder of FibroGen, Inc. is ARMISTICE CAPITAL, LLC, holding approximately 378,000 shares — equal to 9.35% of outstanding shares — as of September 30, 2025.
A total of 33 institutional investors currently hold FGEN stock, with a combined institutional value of approximately $13,869,418 as of the most recent 13F filing period.
Frequently asked questions
FGEN ownershipFibroGen, Inc. (FGEN) is primarily owned by institutional investors, who hold approximately 28.0% of shares. The largest shareholder is ARMISTICE CAPITAL, LLC with a 9.35% stake. Company insiders hold 11.42%. Data sourced from SEC Form 13F as of September 30, 2025.